ArticleSmall (Weinheim an der Bergstrasse, Germany)2025
Controlled Nanoconfinement in a Microfluidic Modular Bead Array Device via Elastomeric Diaphragm Collapse for Enhancing Biomolecular Binding Kinetics.
Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prophage landscapes in clinical MRSA: safety profiling and discovery of Lys81, a broad-spectrum bacteriolytic enzyme.Frontiers in microbiology · 2026Article
- Controlled Nanoconfinement in a Microfluidic Modular Bead Array Device via Elastomeric Diaphragm Collapse for Enhancing Biomolecular Binding Kinetics.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nanoscale confinement strategies alleviate diffusional transport limitations to enhance target binding kinetics with receptors, motivating their utilization for screening and selecting receptors based on binding affinities with target molecules. Herein, a modular and multiplexed device for creating nanoconfinement is presented through the collapse of an elastomeric diaphragm onto microbead arrays immobilized with biomolecules, followed by repeated diaphragm withdrawal to promote bulk transport, thereby enhancing receptor binding kinetics. To repeatedly create controlled nanoconfinement over large spatial extents on the bead, the diaphragm is integrated on its top side with a strain sensor for modulating vertical displacement, while microfabricated nanoposts (≈500 nm depth) on its bottom side control the lateral extent. The modular platform enables facile assembly of beads, each immobilized with different targets into eight microwells for multiplexed screening of receptors, and facile disassembly for quantifying DNA-binding on each bead by downstream q-PCR. Nanoconfinement enhances biomolecular binding at 1 Hz diaphragm pressurization, as validated by rapid DNA immobilization (time constant of ≈6 min vs >60 min under no confinement) and through saturating the binding of target molecules with optimal aptamer candidates (88% site occupancy vs 5% under no confinement at 10 nm levels), thereby screening candidate receptors based on binding affinity parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.